ArticleJournal of cancer research and clinical oncology2019

GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.

Linlin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.